Effects of Adding L-BAIBA to Exercising Adult Overweight and Obese Men and Women on Changes in Body Composition, Glucose Control, and Cardiometabolic Risk Factors

Status: Terminated
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Beta-amino isobutyric acid (BAIBA) is a myokine produced in skeletal muscle and has been shown to impact how our body metabolizes fuel. We seek to examine changes in body composition, weight loss, glucose control, and cardiometabolic risk factors after adding supplementation of BAIBA to exercise in overweight and obese men and women.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: t
View:

• Participants who are between 18 - 60 years of age

• Body mass index values will range from \>25.0 to \< 32.0 kg/m2, making them qualified as an overweight-to-obese population (https://www.nhlbi.nih.gov/health/educational/lose\_wt/BMI/bmicalc.htm)

• Average body mass index for entire study cohort will be less than 30.0 kg/m2. As such an ongoing calculation of the recruited cohort's mean body mass index will be maintained and people will only be randomized into the study if the average cohort body mass index value does not exceed 30.0 kg/m2

• Free-living/uninhibited with use of ambulatory assistive devices (e.g. canes, crutches, walkers, etc.) and independent

• In good health absent of being overweight or mildly obese with no other signs or symptoms of cardiovascular, respiratory, metabolic, immune, psychiatric, or musculoskeletal disease or disorders

• Willingness to maintain consistent sleep duration the evening before study visits

• Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, and carry out all study-related procedures

• Able to complete a peak oxygen consumption exercise test with no contraindications to perform exercise per standards put forth by the American College of Sports Medicine. In other words, they are able to safety complete maximal exercise.

Locations
United States
Missouri
Exercise and Performance Nutrition Laboratory
Saint Charles
Time Frame
Start Date: 2023-03-29
Completion Date: 2024-04-23
Participants
Target number of participants: 23
Treatments
Placebo_comparator: Placebo
Placebo (Resistant Dextrin) (n=40)
Experimental: 750 mg/day Mitoburn (L-BAIBA)
750 mg/day Mitoburn (L-BAIBA)
Experimental: 1,500 mg/day Mitoburn (L-BAIBA)
1,500 mg/day Mitoburn (L-BAIBA)
Related Therapeutic Areas
Sponsors
Leads: Lindenwood University

This content was sourced from clinicaltrials.gov